Mineralys Therapeutics (MLYS) Earnings Date, Estimates & Call Transcripts $29.85 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$29.86 +0.01 (+0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Mineralys Therapeutics Earnings Summary Mineralys Therapeutics posted Q1 2026 earnings on May 6, 2026, reporting an EPS of -$0.47, which beat analysts' consensus estimates of -$0.51 by $0.04. With a trailing EPS of -$2.05, Mineralys Therapeutics' earnings are expected to grow next year, from ($2.30) to ($1.53) per share. Upcoming Q2 Earnings DateAug. 11After Market ClosesEstimatedConsensus EPS (May. 6) -$0.51 Actual EPS (May. 6) -$0.47 Beat By $0.04 Q1 2026 Earnings ResourcesQ1 2026 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)SEC FilingMLYS Upcoming EarningsMineralys Therapeutics' next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules. Powered by Get Mineralys Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataMLYS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Mineralys Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20261-$0.44-$0.44-$0.44Q2 20261-$0.54-$0.54-$0.54Q3 20261-$0.61-$0.61-$0.61Q4 20261-$0.70-$0.70-$0.70 Mineralys Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/11/2026(Estimated)--------5/6/2026Q1 2026-$0.51-$0.47+$0.04-$0.47--3/12/2026Q4 2025-$0.57-$0.40+$0.17-$0.40--11/10/2025Q3 2025-$0.66-$0.52+$0.14-$0.52--8/12/2025Q2 2025-$0.78-$0.66+$0.12-$0.66--5/12/2025Q1 2025-$1.02-$0.79+$0.23-$0.79--2/12/2025Q4 2024-$1.00-$0.98+$0.02-$0.98--11/11/2024Q3 2024-$0.83-$1.13 -$0.30-$1.13--8/13/2024Q2 2024-$0.73-$0.83 -$0.10-$0.83-- Data powered by Fiscal.ai. Mineralys Therapeutics Earnings - Frequently Asked Questions When is Mineralys Therapeutics' earnings date? Mineralys Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 11th, 2026 based off last year's report dates. Learn more on MLYS's earnings history. Did Mineralys Therapeutics beat their earnings estimates last quarter? In the previous quarter, Mineralys Therapeutics (NASDAQ:MLYS) reported ($0.47) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.51) by $0.04. Learn more on analysts' earnings estimate vs. MLYS's actual earnings. How can I listen to Mineralys Therapeutics' earnings conference call? The conference call for Mineralys Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Mineralys Therapeutics' conference call transcript? The conference call transcript for Mineralys Therapeutics' latest earnings report can be read online. Read Transcript How can I view Mineralys Therapeutics' earnings report? Mineralys Therapeutics' earnings report can be found in their filing with the SEC. View SEC filing How much profit does Mineralys Therapeutics generate each year? Mineralys Therapeutics (NASDAQ:MLYS) has a recorded net income of -$154.65 million. MLYS has generated -$2.05 earnings per share over the last four quarters. What is Mineralys Therapeutics' EPS forecast for next year? Mineralys Therapeutics' earnings are expected to grow from ($2.30) per share to ($1.53) per share in the next year. More Earnings Resources from MarketBeat Related Companies CYTK Earnings Date KRYS Earnings Date PRAX Earnings Date IBRX Earnings Date NUVL Earnings Date PCVX Earnings Date QGEN Earnings Date KYMR Earnings Date TGTX Earnings Date PTGX Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half This page (NASDAQ:MLYS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
